The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Semprex     (E)-3-[6-[(E)-1-(4- methylphenyl)-3...

Synonyms: Acrivastin, ACRIVASTINE, Acrivastina, Acrivastinum, CHEMBL1224, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Acrivastin


Psychiatry related information on Acrivastin


High impact information on Acrivastin


Chemical compound and disease context of Acrivastin


Biological context of Acrivastin

  • The mean +/- SD relative bioavailability of acrivastine from colonic compared to oral dosing was 0.18 +/- 0.09 [13].
  • Analysis of AUC values indicated that greater amounts of 270C81 than acrivastine circulated in plasma after both iv and po dosing, and that first-pass metabolism of acrivastine to 270C81 occurred [14].
  • The IC50 (mean +/- SEM) value for the acrivastine-induced inhibition of dV/dt was estimated to be 8.0 +/- 3.7 x 10(-3) M [15].
  • The onset of effect of acrivastine, a new H1-antagonist, has been assessed using antagonism of histamine-induced bronchoconstriction in sensitive volunteers [16].
  • In addition, a trend was demonstrated for both active agents to improve peak expiratory flow rate (PEFR) following exercise, when compared with placebo, and this trend reached statistical significance in the case of acrivastine (p less than 0.05) [17].

Anatomical context of Acrivastin


Associations of Acrivastin with other chemical compounds


Analytical, diagnostic and therapeutic context of Acrivastin


  1. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Brogden, R.N., McTavish, D. Drugs (1991) [Pubmed]
  2. A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma. Berlin, J., King, A.C., Tutsch, K., Findlay, J.W., Kohler, P., Collier, M., Clendeninn, N.J., Wilding, G. Investigational new drugs. (1994) [Pubmed]
  3. Inhibition of histamine or allergen-induced wheals by a single dose of acrivastine, fexofenadine or cetirizine. Ballmer-Weber, B.K., Gex-Collet, C., Wüthrich, B. Journal of investigational allergology & clinical immunology : official organ of the International Association of Asthmology (INTERASMA) and Sociedad Latinoamericana de Alergia e Inmunología. (1999) [Pubmed]
  4. Acrivastine in seasonal allergic rhinitis: two randomized crossover studies to evaluate efficacy and safety. Gibbs, T.G., Irander, K., Salo, O.P. J. Int. Med. Res. (1988) [Pubmed]
  5. An assessment of the novel antihistamine BW 825C in the treatment of chronic idiopathic urticaria. A placebo-controlled study. Gibson, J.R., Harvey, S.G., Barth, J.H., Moss, M.Y., Burke, C.A. Dermatologica (1984) [Pubmed]
  6. The acute effects of acrivastine (BW825C), a new antihistamine, compared with triprolidine on measures of central nervous system performance and subjective effects. Cohen, A.F., Hamilton, M., Philipson, R., Peck, A.W. Clin. Pharmacol. Ther. (1985) [Pubmed]
  7. Urticaria. Recognition, causes and treatment. Ormerod, A.D. Drugs (1994) [Pubmed]
  8. Effects of semprex-D and diphenhydramine on learning in young adults with seasonal allergic rhinitis. Vuurman, E.F., van Veggel, L.M., Sanders, R.L., Muntjewerff, N.D., O'Hanlon,, J.F. Ann. Allergy Asthma Immunol. (1996) [Pubmed]
  9. A comparison of acrivastine versus terfenadine and placebo in the treatment of chronic idiopathic urticaria. van Joost, T., Blog, F.B., Westerhof, W., Jansen, F.C., Starink, T.M., den Boer, M.S., Kuneman, J.J., Harvey, S.G., Gibson, J.R. J. Int. Med. Res. (1989) [Pubmed]
  10. A comparison of acrivastine versus clemastine and placebo in the treatment of patients with chronic idiopathic urticaria. Leyh, F., Harvey, S.G., Gibson, J.R., Manna, V.K. J. Int. Med. Res. (1989) [Pubmed]
  11. A comparison of acrivastine versus chlorpheniramine in the treatment of chronic idiopathic urticaria. Gale, A.E., Harvey, S.G., Calthrop, J.G., Gibson, J.R. J. Int. Med. Res. (1989) [Pubmed]
  12. A comparison of acrivastine versus hydroxyzine and placebo in the treatment of chronic idiopathic urticaria. Salo, O.P., Harvey, S.G., Calthrop, J.G., Gibson, J.R. J. Int. Med. Res. (1989) [Pubmed]
  13. Pharmacokinetics of acrivastine after oral and colonic administration. Balasubramanian, R., Klein, K.B., Pittman, A.W., Liao, S.H., Findlay, J.W., Frosolono, M.F. Journal of clinical pharmacology. (1989) [Pubmed]
  14. Disposition of acrivastine in the male beagle dog. McNulty, M.J., Deal, D.L., Nelson, F.R., Weller, S., Chandrasurin, P., Shockcor, J., Findlay, J.W. Drug Metab. Dispos. (1992) [Pubmed]
  15. Terfenadine alters action potentials in isolated canine Purkinje fibers more than acrivastine. Lang, D.G., Wang, C.M., Wenger, T.L. J. Cardiovasc. Pharmacol. (1993) [Pubmed]
  16. The onset of effect of the H1-antagonist acrivastine ("Semprex") assessed by histamine bronchial challenge in volunteers. Rolan, P.E., Phillips, S., Adams, J., Posner, J. Eur. J. Clin. Pharmacol. (1990) [Pubmed]
  17. Acrivastine versus hydroxyzine in the treatment of cholinergic urticaria. A placebo-controlled study. Kobza Black, A., Aboobaker, J., Gibson, J.R., Harvey, S.G., Marks, P. Acta Derm. Venereol. (1988) [Pubmed]
  18. Efficacy of acrivastine plus pseudoephedrine for symptomatic relief of seasonal allergic rhinitis due to mountain cedar. Williams, B.O., Hull, H., McSorley, P., Frosolono, M.F., Sanders, R.L. Ann. Allergy Asthma Immunol. (1996) [Pubmed]
  19. Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Mahar Doan, K.M., Wring, S.A., Shampine, L.J., Jordan, K.H., Bishop, J.P., Kratz, J., Yang, E., Serabjit-Singh, C.J., Adkison, K.K., Polli, J.W. Pharmacology (2004) [Pubmed]
  20. Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. Mann, R.D., Pearce, G.L., Dunn, N., Shakir, S. BMJ (2000) [Pubmed]
  21. Acupuncture plus point-injection for 32 cases of obstinate urticaria. Zhao, Y. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan / sponsored by All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine. (2006) [Pubmed]
  22. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Reimers, A., Pichler, C., Helbling, A., Pichler, W.J., Yawalkar, N. Clin. Exp. Allergy (2002) [Pubmed]
  23. Quantification of antihistamine acrivastine in plasma by solid-phase extraction and high-performance liquid chromatography. Collins, B.R., Gu, X. Journal of pharmaceutical and biomedical analysis (2007) [Pubmed]
  24. Pharmacodynamic and pharmacokinetics of BW 825C: a new antihistamine. Cohen, A.F., Hamilton, M.J., Liao, S.H., Findlay, J.W., Peck, A.W. Eur. J. Clin. Pharmacol. (1985) [Pubmed]
WikiGenes - Universities